---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-253143"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:34:06.388885+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atea Q3 net loss $31.2M (-$0.37/sh); COVID-19 Phase 3 fails, HCV topline Dec 2024

## Summary
- Net loss $31.2M ($0.37 diluted EPS) vs $33.1M loss ($0.40) YoY; cash $482.8M at Sept 30.
- Phase 3 SUNRISE-3 COVID-19 trial missed primary endpoint; no regulatory path pursued.
- Phase 2 HCV study (n=275) topline SVR12 results expected early Dec 2024; FDA End-of-Phase 2 meeting planned Q1 2025.
- R&D spend $26.2M, down $2.0M YoY due to lower COVID spend offset by higher HCV costs.

## SEC filing metadata
- accession: 0001193125-24-253143
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/0001193125-24-253143-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312524253143/d841992d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-253143
- JSON: https://secwatch.observer/filing/0001193125-24-253143.json
- Plain text: https://secwatch.observer/filing/0001193125-24-253143.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.